State-of-the-art pharmacological approaches to reduce chorea in Huntington’s disease

References

• Huntington G. On chorea. J Neuropsychiatry Clin Neurosci. 2003;15(1):109–112.
   PubMed Web of Science ®Google Scholar
• Galvan L, André VM, Wang EA, et al. Functional differences between direct and indirect striatal output pathways in Huntington’s disease. J Huntingtons Dis. 2012;1(1):17–25.
   PubMedGoogle Scholar
• Albin RL, Reiner A, Anderson KD, et al. Striatal and nigral neuron subpopulations in rigid Huntington’s disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann Neurol. 1990;27(4):357–365.
   PubMed Web of Science ®Google Scholar
• Ghosh R, Tabrizi SJ. Clinical features of Huntington’s disease. Adv Exp Med Biol. 2018;1049:1–28.
   PubMed Web of Science ®Google Scholar
• van de Zande NA, Massey TH, McLauchlan D, et al. Clinical characterization of dystonia in adult patients with Huntington’s disease. Eur J Neurol. 2017;24(9):1140–1147.
   PubMed Web of Science ®Google Scholar
• Squitieri F, Berardelli A, Nargi E, et al. Atypical movement disorders in the early stages of Huntington’s disease: clinical and genetic analysis. Clin Genet. 2000;58(1):50–56.
   PubMed Web of Science ®Google Scholar
• Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington’s disease. J Neurol Neurosurg Psychiatry. 1998;65(4):577–579.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Bhatia KP, Brown P, et al. Cortical myoclonus in Huntington’s disease. Mov Disord. 1994;9(6):633–641.
   PubMed Web of Science ®Google Scholar
• Cui SS, Ren RJ, Wang Y, et al. Tics as an initial manifestation of juvenile Huntington’s disease: case report and literature review. BMC Neurol. 2017;17(1):152.
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J. 2004;80(947):527–534.
   PubMed Web of Science ®Google Scholar
• Sherman CW, Iyer R, Abler V, et al. Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): a qualitative analysis of individuals across the HD spectrum, family members, and clinicians. Neuropsychol Rehabil. 2020;30(6):1150–1168.
   PubMed Web of Science ®Google Scholar
• Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547–559.
   PubMedGoogle Scholar
• Sitek EJ, Thompson JC, Craufurd D, et al. Unawareness of deficits in Huntington’s disease. J Huntingtons Dis. 2014;3(2):125–135.
   PubMedGoogle Scholar
• Isaacs D, Gibson JS, Stovall J, et al. The impact of anosognosia on clinical and patient-reported assessments of psychiatric symptoms in Huntington’s disease. J Huntingtons Dis. 2020;9(3):291-302.
   PubMed Web of Science ®Google Scholar
• Simpson JA, Lovecky D, Kogan J, et al. Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395–403.
   PubMed Web of Science ®Google Scholar
• Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington study group. Mov Disord. 1996 Mar;11(2):136–142.
   PubMed Web of Science ®Google Scholar
• Penney JB Jr., Young AB, Shoulson I, et al. Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5(2):93–99.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006 Feb 14;66(3):366–372.
   PubMed Web of Science ®Google Scholar
• Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. Jama. 2016;316(1):40–50.
   PubMed Web of Science ®Google Scholar
• Reilmann R, Bohlen S, Kirsten F, et al. Assessment of involuntary choreatic movements in Huntington’s disease–toward objective and quantitative measures. Mov Disord. 2011;26(12):2267–2273.
   PubMed Web of Science ®Google Scholar
• de Boo G, Tibben A, Hermans J, et al. Subtle involuntary movements are not reliable indicators of incipient Huntington’s disease. Mov Disord. 1998;13(1):96–99.
   PubMed Web of Science ®Google Scholar
• Mestre TA, Forjaz MJ, Mahlknecht P, et al. Rating scales for motor symptoms and signs in Huntington’s disease: critique and recommendations. Mov Disord Clin Pract. 2018;5(2):111–117.
   PubMed Web of Science ®Google Scholar
• Johnson EB, Rees EM, Labuschagne I, et al. The impact of occipital lobe cortical thickness on cognitive task performance: an investigation in Huntington’s Disease. Neuropsychologia. 2015;79(Pt A):138–146.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42–53.
   PubMed Web of Science ®Google Scholar
• Rosenblatt A, Ranen NG, Nance MA, et al. A physician’s guide to the management of Huntington’s disease. New York: Huntington’s Disease Society of America; 1999.
   Google Scholar
• Fish DR, Sawyers D, Allen PJ, et al. The effect of sleep on the Dyskinetic movements of Parkinson’s Disease, Gilles de la Tourette Syndrome, Huntington’s disease, and Torsion Dystonia. Arch Neurol. 1991;48(2):210–214.
   PubMedGoogle Scholar
• Hurelbrink CB, Lewis SJ, Barker RA. The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington’s disease. J Neurol. 2005;252(6):642–647.
   PubMed Web of Science ®Google Scholar
• Ranjan S, Kohler S, Harrison MB, et al. Nocturnal post-arousal chorea and repetitive ballistic movement in Huntington’s disease. Mov Disord Clin Pract. 2016;3(2):200–202.
   PubMed Web of Science ®Google Scholar
• Goodman AO, Rogers L, Pilsworth S, et al. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington’s disease. Curr Neurol Neurosci Rep. 2011;11(2):211–217.
   PubMed Web of Science ®Google Scholar
• Andrzejewski KL, Dowling AV, Stamler D, et al. Wearable sensors in Huntington disease: a pilot study. J Huntingtons Dis. 2016;5(2):199–206.
   PubMed Web of Science ®Google Scholar
• Gordon MF, Grachev ID, Mazeh I, et al. Quantification of motor function in Huntington disease patients using wearable sensor devices. Digital Biomarkers. 2019;3(3):103–115.
   PubMedGoogle Scholar
• Adams JL, Dinesh K, Xiong M, et al. Multiple wearable sensors in Parkinson and Huntington disease individuals: a pilot study in clinic and at home. Digital Biomarkers. 2017;1(1):52–63.
   PubMedGoogle Scholar
• Waugh JL, Miller VS, Chudnow RS, et al. Juvenile Huntington disease exacerbated by methylphenidate: case report. J Child Neurol. 2008;23(7):807–809.
   PubMed Web of Science ®Google Scholar
• Hamilton CJ, Timmer TK, Munjal RC, et al. Worsening choreoathetosis in Huntington’s disease with Fluoxetine, Lisdexamfetamine, and Melatonin: a case report. Innov Clin Neurosci. 2018;15(7–8):27–31.
   PubMedGoogle Scholar
• Schultz JL, Kamholz JA, Moser DJ, et al. Substance abuse may hasten motor onset of Huntington disease: evaluating the Enroll-HD database. Neurology. 2017;88(9):909–915.
   PubMed Web of Science ®Google Scholar
• Glidden AM, Luebbe EA, Elson MJ, et al. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020;94(19):e2045-e2053.
   Web of Science ®Google Scholar
• Harris KL, Kuan WL, Mason SL, et al. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington’s disease (Enroll-HD). J Neurol Neurosurg Psychiatry. 2020;91(6):622-630.
   Web of Science ®Google Scholar
• Diehl SK, Mefferd AS, Lin YC, et al. Motor speech patterns in Huntington disease. Neurology. 2019;93(22):e2042–e52.
   PubMed Web of Science ®Google Scholar
• Sung VW, Iyer RG, Gandhi SK, et al. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States. Curr Med Res Opin. 2018;34(4):643–648.
   PubMed Web of Science ®Google Scholar
• Priller J, Ecker D, Landwehrmeyer B, et al. Europe-wide assessment of current medication choices in Huntington’s disease. Mov Disord. 2008;23(12):1788.
   PubMed Web of Science ®Google Scholar
• Videnovic A. Treatment of huntington disease. Curr Treat Options Neurol. 2013;15(4):424–438.
   PubMed Web of Science ®Google Scholar
• McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry. 2006;189(5):433–440.
   PubMed Web of Science ®Google Scholar
• Martino D, Karnik V, Osland S, et al. Movement disorders associated with antipsychotic medication in people with Schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. 2018;63(11):706743718777392.
   PubMed Web of Science ®Google Scholar
• Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington’s disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1984;47(8):844–847.
   PubMed Web of Science ®Google Scholar
• Deroover J, Baro F, Bourguignon RP, et al. Tiapride versus placebo: a double-blind comparative study in the management of Huntington’s chorea. Curr Med Res Opin. 1984;9(5):329–338.
   PubMed Web of Science ®Google Scholar
• Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington’s disease. J Neurol Neurosurg Psychiatry. 1984;47(8):848–852.
   PubMed Web of Science ®Google Scholar
• Desamericq G, Dolbeau G, Verny C, et al. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. PLoS One. 2014;9(1):e85430.
   PubMed Web of Science ®Google Scholar
• Cankurtaran ES, Ozalp E, Soygur H, et al. Clinical experience with risperidone and memantine in the treatment of Huntington’s disease. J Natl Med Assoc. 2006;98(8):1353–1355.
   PubMed Web of Science ®Google Scholar
• Dallocchio C, Buffa C, Tinelli C, et al. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19(1):101–103.
   PubMed Web of Science ®Google Scholar
• Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20(1):1–3.
   PubMed Web of Science ®Google Scholar
• Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington’s disease. Eur J Neurol. 2002;9(2):182–183.
   PubMed Web of Science ®Google Scholar
• Johnston TG. Risperidone long-acting injection and Huntington’s disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol. 2011;26(2):114–119.
   PubMed Web of Science ®Google Scholar
• Meco G, Bonifati V, Alessandri A, et al. Risperidone in Huntington's disease. Human Psychopharmacology: Clinical and Experimental. 1995;10(4):353–354.
   Google Scholar
• Parsa MA, Szigethy E, Voci JM, et al. Risperidone in treatment of choreoathetosis of Huntington’s disease. J Clin Psychopharmacol. 1997;17(2):134–135.
   PubMed Web of Science ®Google Scholar
• Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington’s disease: a pilot study. J Psychopharmacol. 1996;10(2):162–165.
   PubMed Web of Science ®Google Scholar
• Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington’s disease. J Clin Psychopharmacol. 2001;21(2):245–246.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G, Tribl GG, et al. High-dose olanzapine in Huntington’s disease. Int Clin Psychopharmacol. 2002;17(2):91–93.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25(5):263–265.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G, Diez J, et al. Riluzole and olanzapine in Huntington’s disease. Eur J Neurol. 2002;9(2):183–184.
   PubMed Web of Science ®Google Scholar
• Dipple HC. The use of olanzapine for movement disorder in Huntington’s disease: a first case report. J Neurol Neurosurg Psychiatry. 1999;67(1):123–124.
   PubMed Web of Science ®Google Scholar
• Grove VE Jr., Quintanilla J, DeVaney GT. Improvement of Huntington’s disease with olanzapine and valproate. N Engl J Med. 2000;343(13):973–974.
   PubMed Web of Science ®Google Scholar
• Laks J, Rocha M, Capitao C, et al. Functional and motor response to low dose olanzapine in Huntington’s disease: case report. Arq Neuropsiquiatr. 2004;62(4):1092–1094.
   PubMed Web of Science ®Google Scholar
• Paleacu D, Anca M, Giladi N. Olanzapine in Huntington’s disease. Acta Neurol Scand. 2002;105(6):441–444.
   PubMed Web of Science ®Google Scholar
• Skocic M, Dujmovic J, Jevtovic S, et al. Premorbid combat related ptsd in Huntington’s disease - Case report. Psychiatr Danub. 2010;22(2):286–288.
   PubMed Web of Science ®Google Scholar
• Squitieri F, Cannella M, Porcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(1):69–72.
   PubMedGoogle Scholar
• Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009;24(1):126–129.
   PubMed Web of Science ®Google Scholar
• Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatr Dis Treat. 2009;5:1–4.
   PubMed Web of Science ®Google Scholar
• Edlinger M, Seppi K, Fleischhacker W, et al. Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington’s disease. Int Clin Psychopharmacol. 2013;28(4):214–216.
   PubMed Web of Science ®Google Scholar
• Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington’s disease. Am J Psychiatry. 2008;165(9):1207–1208.
   PubMed Web of Science ®Google Scholar
• Oulis P, Mourikis I, Konstantakopoulos G, et al. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2010;22(3):352c.e4–52.e5.
   Web of Science ®Google Scholar
• Yavuz KF, Ulusoy S, Alniak I. Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2013;25(2):E31.
   PubMed Web of Science ®Google Scholar
• Ding J, Gadit AM. Psychosis with Huntington’s disease: role of antipsychotic medications. BMJ Case Rep. 2014;2014:bcr2013202625.
   Google Scholar
• Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington’s disease. Am J Geriatr Psychiatry England. 1998;347–349.
   PubMed Web of Science ®Google Scholar
• Xu C, Yogaratnam J, Tan N, et al. Psychosis, treatment emergent extrapyramidal events, and subsequent onset of Huntington’s disease: a case report and review of the literature. Clin Psychopharmacol Neurosci. 2016;14(3):302–304.
   PubMed Web of Science ®Google Scholar
• Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of Schizophrenia: past, present and future. Curr Top Med Chem. 2016;16(29):3385–3403.
   PubMed Web of Science ®Google Scholar
• Arciniegas DB. Psychosis. Continuum (Minneap Minn). 2015;21(3Behavioral Neurology and Neuropsychiatry):715–736.
   PubMedGoogle Scholar
• Morigaki R, Goto S. Striatal Vulnerability in Huntington’s Disease: neuroprotection Versus Neurotoxicity. Brain Sci. 2017;7(6):63.
   Web of Science ®Google Scholar
• American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.
   PubMed Web of Science ®Google Scholar
• Fang F, Sun H, Wang Z, et al. Antipsychotic drug-induced somnolence: incidence, mechanisms, and management. CNS Drugs. 2016;30(9):845–867.
   PubMed Web of Science ®Google Scholar
• Howard AK, Krishnamoorthy A, Leavitt BR, et al. Treatment of Huntington disease and Comorbid Trichotillomania with aripiprazole. J Neuropsychiatry Clin Neurosci. 2015;27(3):e211–2.
   PubMed Web of Science ®Google Scholar
• Lazowski LK, Townsend B, Hawken ER, et al. Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial. BMC Psychiatry. 2014;17(14):202.
   Web of Science ®Google Scholar
• Pae CU, Serretti A, Patkar AA, et al. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs. 2008;22(5):367–388.
   PubMed Web of Science ®Google Scholar
• Van Vugt JPP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study. J Neurol Neurosurg. 1997;63(1):35–39.
   PubMed Web of Science ®Google Scholar
• Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136(3):317-320.
   Web of Science ®Google Scholar
• Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47(1):70–72.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Niederwieser G. Quetiapine in Huntington’s disease: a first case report. J Neurol. 2002;249(8):1114–1115.
   PubMed Web of Science ®Google Scholar
• Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to huntington’s disease: a case report. Can J Psychiatry. 2004;49(6):413.
   PubMed Web of Science ®Google Scholar
• Koch J, Shi WX, Dashtipour K. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacol Ther. 2020;212:107580.
   PubMed Web of Science ®Google Scholar
• Schuldiner S, Liu Y, Edwards RH. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J Biol Chem. 1993;268(1):29–34.
   PubMed Web of Science ®Google Scholar
• Schultz JL, Killoran A, Nopoulos PC, et al. Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology. 2018;91(3):e202–e07.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Brocht AF, Nichols PE, et al. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. J Huntingtons Dis. 2013;2(4):509–515.
   PubMedGoogle Scholar
• Xenazine. Package insert. Deerfield, Il: Lundbeck; 2019.
   Google Scholar
• AUSTEDO- deutetrabenazine tablet, coated [package insert]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf
   Google Scholar
• Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4(1):3.
   PubMedGoogle Scholar
• Ingrezza. Package insert. San Diego, CA: Neurocrine Biosciences, Inc; 2019.
   Google Scholar
• Rodrigues FB, Duarte GS, Costa J, et al. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: twins or Distant Cousins? Mov Disord Clin Pract. 2017;4(4):582–585.
   PubMed Web of Science ®Google Scholar
• Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of Chorea. JAMA Neurol. 2017;74(8):977–982.
   PubMed Web of Science ®Google Scholar
• Thompson JC, Harris J, Sollom AC, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2012;24(1):53–60.
   PubMed Web of Science ®Google Scholar
• Burgunder J-M, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr. 2011;3:RRN1260.
   PubMedGoogle Scholar
• Zesiewicz TA, Sullivan KL, Hauser RA, et al. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease. Mov Disord. 2006;21(11):1998–2001.
   PubMed Web of Science ®Google Scholar
• Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington’s disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694–699.
   PubMed Web of Science ®Google Scholar
• O’Suilleabhain P, Dewey, Jr RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60(7):996–998.
   PubMed Web of Science ®Google Scholar
• de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–1057.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group HI. A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165–176.
   PubMed Web of Science ®Google Scholar
• McGarry A, Auinger P, Kieburtz K, et al. Additional safety and exploratory efficacy data at 48 and 60 months from open-HART, an open-label extension study of pridopidine in Huntington disease. J Huntingtons Dis. 2020;9(2):173–184.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism relat disord. 2007;13(7):453–454
   Google Scholar
• Zittel S, Tadic V, Moll CKE, et al. Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington’s disease. Parkinsonism Relat Disord. 2018;51:96–100.
   PubMed Web of Science ®Google Scholar
• Delorme C, Rogers A, Lau B, et al. Deep brain stimulation of the internal pallidum in Huntington’s disease patients: clinical outcome and neuronal firing patterns. J Neurol. 2016;263(2):290–298.
   PubMed Web of Science ®Google Scholar
• Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121(1):114–122.
   PubMed Web of Science ®Google Scholar
• Wojtecki L, Groiss SJ, Ferrea S, et al. A prospective pilot trial for Pallidal deep brain stimulation in Huntington’s disease. Front Neurol. 2015;6:177.
   PubMed Web of Science ®Google Scholar
• Byars JA, Beglinger LJ, Moser DJ, et al. Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol. 2012;259(9):1824–1831.
   PubMed Web of Science ®Google Scholar
• Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci USA. 2004;101(10):3498–3503.
   PubMed Web of Science ®Google Scholar
• Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington’s disease. Arch Neurol. 1991;48(8):800–804.
   PubMedGoogle Scholar
• Busse M, Quinn L, Debono K, et al. A randomized feasibility study of a 12-week community-based exercise program for people with Huntington’s disease. J Neurol Phys Ther. 2013;37(4):149–158.
   PubMed Web of Science ®Google Scholar
• Frese S, Petersen JA, Ligon-Auer M, et al. Exercise effects in Huntington disease. J Neurol. 2017;264(1):32–39.
   PubMed Web of Science ®Google Scholar
• Khalil H, Quinn L, van Deursen R, et al. What effect does a structured home-based exercise programme have on people with Huntington’s disease? A randomized, controlled pilot study. Clin Rehabil. 2013;27(7):646–658.
   PubMed Web of Science ®Google Scholar
• Quinn L, Hamana K, Kelson M, et al. A randomized, controlled trial of a multi-modal exercise intervention in Huntington’s disease. Parkinsonism Relat Disord. 2016;31:46–52.
   PubMed Web of Science ®Google Scholar
• for FCC, Research CE. Report to the President and the Congress In: Services DoHaH, ed. 2009.
   Google Scholar
• Gibson JS, Ridner SH, Dietrich MS, et al. Measuring functional status in Huntington’s disease. Mov Disord. 2020;27. doi: 10.1002/mds.28363.
   Web of Science ®Google Scholar